| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.046 | 3.251 | 36.941 | 37.862 | 28.538 | 0 | 1.294 | 65 | 0 | 0 |
| Total Income - EUR | 17.046 | 3.251 | 36.941 | 38.079 | 28.539 | 1 | 6.025 | 65 | 0 | 0 |
| Total Expenses - EUR | 10.535 | 5.294 | 21.195 | 16.612 | 22.373 | 5.519 | 6.662 | 214 | 110 | 0 |
| Gross Profit/Loss - EUR | 6.511 | -2.043 | 15.747 | 21.467 | 6.166 | -5.518 | -638 | -149 | -110 | 0 |
| Net Profit/Loss - EUR | 6.000 | -2.146 | 14.638 | 20.331 | 5.309 | -5.518 | -819 | -151 | -110 | 0 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Mihmed Pharma Line Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 65 | 13.724 | 11.093 | 8.484 | 6.004 | 276 | 111 | 0 | 0 |
| Current Assets | 35.749 | 27.774 | 29.067 | 50.740 | 67.264 | 48.901 | 52.553 | 46.656 | 46.515 | 46.255 |
| Inventories | 1.903 | 1.281 | 5.144 | 2.454 | 2.373 | 2.328 | 1.464 | 1.421 | 1.416 | 1.408 |
| Receivables | 1.359 | 312 | 4.746 | 316 | 11.864 | 161 | 121 | 187 | 187 | 186 |
| Cash | 32.488 | 26.181 | 19.177 | 47.970 | 53.028 | 46.412 | 50.967 | 45.048 | 44.912 | 44.661 |
| Shareholders Funds | 30.294 | 27.839 | 42.007 | 61.567 | 65.684 | 53.494 | 46.435 | 46.428 | 46.177 | 42.300 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 6.422 | 0 | 795 | 267 | 10.081 | 1.412 | 6.394 | 338 | 337 | 3.954 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Mihmed Pharma Line Srl